Table 1 Pathway analysis of RS4;11 and SEM exposed to AraC, DEX and IDEL and two drugs combined (AraC + IDEL, DEX + IDEL)
Pathway (regulation) AraC + IDEL vs. AraC vs. IDEL | Pathway: ranking position (corresponding genes) | Cell line | ||
|---|---|---|---|---|
AraC + IDEL | AraC | IDEL | ||
Retinoblastoma in Cancer (up) | 10 (16) | 90 (4) | 87 (2) | RS4;11 |
TGF-beta signaling pathway (down) | 19 (12) | 31 (3) | 90 (1) | |
TGF-beta signaling PATHWAY (up) | 17 (19) | 37 (13) | – | SEM |
SIDS susceptibility pathway (up) | 19 (18) | 35 (14) | – | |
TNF-alpha signaling pathway (up) | 20 (18) | 34 (15) | – | |
Pathway (regulation) DEX + IDEL vs. DEX vs. IDEL | DEX + IDEL | DEX | IDEL | Cell line |
|---|---|---|---|---|
Proteasome degradation (down) | 19 (28) | 52 (10) | – | RS4;11 |
Cytoplasmic ribosomal proteins (up) | 1 (42) | 72 (5) | – | SEM |
MicroRNAs in cardiomyocyte hypertrophy (up) | 16 (18) | 31 (10) | 30 (1) | |
Ectoderm differentiation (up) | 19 (17) | 39 (8) | – | |
Retinoblastoma in cancer (down) | 1 (55) | 46 (10) | 135 (1) | |
Cell cycle (down) | 2 (51) | 32 (12) | 56 (2) | |
DNA replication (down) | 5 (32) | 80 (6) | – | |
G1 to S cell cycle (down) | 6 (32) | 53 (9) | 62 (2) | |
DNA damage response (down) | 13 (24) | 37 (11) | 58 (2) |